Silenor

Insomnia, Neurotic depression, Depression + 8 more

Treatment

20 Active Studies for Silenor

What is Silenor

Doxepin

The Generic name of this drug

Treatment Summary

Doxepin is a medication used to treat depression and anxiety. It belongs to a class of drugs called tricyclic antidepressants, but it does not have the same exact properties as them. Doxepin was first approved by the FDA in 1969 for use as an antidepressant and was later approved in 2010 for the treatment of insomnia. It was developed by Pfizer and is available under the brand name Silenor.

Sinequan

is the brand name

image of different drug pills on a surface

Silenor Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Sinequan

Doxepin

1969

307

Effectiveness

How Silenor Affects Patients

Doxepin is a type of antidepressant that works by decreasing electrical activity in the brain. It can cause antidepressant, sedative, and anticholinergic effects, but at higher doses the anticholinergic and antiadrenergic properties become more prominent. The antidepressant effects of doxepin become noticeable after 2 weeks, while the sedative effects can be seen right away.

How Silenor works in the body

Doxepin works by blocking histamine receptors, which helps to treat skin conditions. Additionally, it works on the central nervous system to increase the activity of norepinephrine and serotonin, which are neurotransmitters. This increases the activity at the post-synaptic neuron receptor sites. Doxepin also desensitizes serotonin 1A receptors and beta-adrenergic receptors. Lastly, it is thought to increase dopamine activity in the frontal cortex.

When to interrupt dosage

The dosage of Silenor is contingent upon the identified condition, including Depression, Involutional, Mental Disorder, Organic and Insomnia. The measure of dosage is contingent upon the technique of application (e.g. Oral or Tablet - Oral) featured in the table beneath.

Condition

Dosage

Administration

Insomnia

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule - Oral, Capsule, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Neurotic depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule - Oral, Capsule, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule - Oral, Capsule, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Generalized Anxiety Disorder

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule - Oral, Capsule, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Neuropathic Pain

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule - Oral, Capsule, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Itching

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule - Oral, Capsule, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule - Oral, Capsule, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Behcet Syndrome

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule - Oral, Capsule, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Alcoholism

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule - Oral, Capsule, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule - Oral, Capsule, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Neurodermatitis

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule - Oral, Capsule, Topical, Cream, Cream - Topical, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

Silenor Contraindications

Condition

Risk Level

Notes

untreated narrow angle glaucoma

Do Not Combine

Pulse Frequency

Do Not Combine

Urinary Retention

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Doxepin may interact with Pulse Frequency

There are 20 known major drug interactions with Silenor.

Common Silenor Drug Interactions

Drug Name

Risk Level

Description

4-Methoxyamphetamine

Major

Doxepin may increase the vasopressor activities of 4-Methoxyamphetamine.

Acepromazine

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Doxepin is combined with Aclidinium.

Alfuzosin

Major

Doxepin may increase the hypotensive activities of Alfuzosin.

Aripiprazole

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Silenor Toxicity & Overdose Risk

Taking too much doxepin can cause seizures, irregular heartbeat, unconsciousness, low blood pressure, and depression of the central nervous system. It can also lead to changes in electrocardiogram results and even death. Additionally, doxepin affects fertility in men and women, leading to decreased implantation and litter size, as well as abnormal sperm and reduced sperm motility. There is no evidence that it causes cancer or genetic mutations.

Silenor Novel Uses: Which Conditions Have a Clinical Trial Featuring Silenor?

Currently, 1020 active studies are looking into the potential of Silenor to provide relief from Generalized Anxiety Disorder, Atopic Dermatitis and Bipolar Disorder.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

181 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3, Phase 1

Depressive Disorder, Major

0 Actively Recruiting

Insomnia

0 Actively Recruiting

Depression

300 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Alcoholism

7 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Neurotic depression

0 Actively Recruiting

Depressive Disorder, Major

0 Actively Recruiting

Itching

3 Actively Recruiting

Phase 3, Not Applicable

Behcet Syndrome

1 Actively Recruiting

Not Applicable

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Neurodermatitis

0 Actively Recruiting

Silenor Reviews: What are patients saying about Silenor?

5

Patient Review

6/15/2016

Silenor for Chronic Trouble Sleeping

I've been using this treatment for two weeks and it's helped me stay asleep through the night. At first I felt groggy during the day, but that has passed. Now I'm really pleased with how well it works.

5

Patient Review

5/12/2016

Silenor for Chronic Trouble Sleeping

This was very easy to use, and it worked immediately.

5

Patient Review

2/22/2018

Silenor for Chronic Trouble Sleeping

I find that if I eat dinner no later than 6:30 PM and then take Silenor at 10:30 PM, I sleep really well. Before taking this medication, I would average 4 to 5 hours of sleep per night; however, now I'm averaging 7.5 hours of sleep per night.

4.7

Patient Review

3/14/2016

Silenor for Chronic Trouble Sleeping

Before taking Silenor, I was only sleeping for two to four hours per night. This medication doesn't make you fall asleep, but it does help you stay asleep once you do fall asleep. It's been a lifesaver.

4.3

Patient Review

9/22/2014

Silenor for Chronic Trouble Sleeping

I've been using Ambien for a while now, and unfortunately my body became used to it after a few years. Thankfully, my doctor recommended that I also take Silenor in order to combat this problem. So far it's working great!

4.3

Patient Review

10/17/2016

Silenor for Chronic Trouble Sleeping

I love how this treatment helps me sleep, but unfortunately I have to be careful not to use it more than a couple nights in a row or else I get a dry mouth.

2.7

Patient Review

4/28/2018

Silenor for Chronic Trouble Sleeping

This drug helped me sleep at first, but after a few weeks I started experiencing some bad side effects. The worst was memory loss; I would constantly forget things or do something and then completely forget about it. It also made my depression and anxiety much worse. Do not take more than prescribed, as I made this mistake and slept for over 24 hours straight. Would not recommend this drug.

2.3

Patient Review

5/9/2015

Silenor for Chronic Trouble Sleeping

I have been taking this medication for a week now and it keeps me up all night. I would not recommend it to anyone.

2.3

Patient Review

8/29/2016

Silenor for Chronic Trouble Sleeping

Unfortunately, this did not help me fall asleep at all. As a result, I've gotten no sleep and feel pretty terrible.

2.3

Patient Review

12/21/2014

Silenor for Chronic Trouble Sleeping

This medication definitely keeps me awake; however, it also gives me weird and intrusive thoughts. Additionally, I feel like the room temperature is significantly warmer than it actually is.

2

Patient Review

7/24/2018

Silenor for Chronic Trouble Sleeping

This drug was sometimes effective when I took it to sleep, but not always. At $25 a bottle, it was worth trying. However, now that the price has gone up to $100 for a 30 day supply, it's not worth it anymore.

1.7

Patient Review

11/6/2016

Silenor for Chronic Trouble Sleeping

I would not recommend this drug to anyone. It caused me severe depression and crying fits, and did nothing to help my insomnia.

1.7

Patient Review

11/1/2015

Silenor for Chronic Trouble Sleeping

Ambien only helped me sleep for four hours, so I decided to try this treatment. The first night, I woke up after only one hour of sleep. The second night, I took two doses and slept for an extra hour... but that still wasn't enough. This didn't work for me at all.

1.7

Patient Review

11/10/2019

Silenor for Chronic Trouble Sleeping

PSA - I was prescribed doxepin for insomnia and anxiety. After a lower dose was not effective, my Dr. increased the dose. The first night on the increased dose, I slept drove and was arrested for a DUI. I also had significant memory issues during the several months I was prescribed doxepin and which have persisted. Upon discontinuing doxepin, side effects ceased. Take with EXTREME CAUTION

1.7

Patient Review

7/24/2018

Silenor for Chronic Trouble Sleeping

I halved the Silenor tablet my doctor prescribed me for insomnia after the first dose made me feel like a zombie the next day. Even halving the dosage leaves me feeling drowsy and barely functional for several hours afterward, so it's not worth it to me.

1

Patient Review

10/15/2016

Silenor for Chronic Trouble Sleeping

This treatment was ineffective for me and made it harder to function the next day. I wouldn't recommend it to anyone with chronic insomnia.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about silenor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does it take for Silenor to kick in?

"After taking doxepin, you should limit your activities to those necessary to prepare for sleep. Doxepin works best when taken 3 hours after a meal and within 30 minutes of bedtime."

Answered by AI

What are the side effects of Silenor?

"trouble sleeping

Drowsiness, dizziness, stuffy nose, sneezing, sore throat, nausea, vomiting, diarrhea, constipation, loss of appetite, and trouble sleeping are all symptoms of the cold."

Answered by AI

Is Silenor a narcotic?

"The manufacturer of Silenor claims that it is a non-abusable option for insomnia relief and is not classified as a controlled substance by the DEA."

Answered by AI

Is Silenor a good sleeping pill?

"Doxepin is a medication used to treat insomnia. It is in a class of medications called tricyclic antidepressants. Doxepin works by slowing activity in the brain to allow sleep."

Answered by AI

Clinical Trials for Silenor

Have you considered Silenor clinical trials?

We made a collection of clinical trials featuring Silenor, we think they might fit your search criteria.
Go to Trials
Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Have you considered Silenor clinical trials?

We made a collection of clinical trials featuring Silenor, we think they might fit your search criteria.
Go to Trials
Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of Fort Bend ISD in Sugar Land, United States.

Wellbeing Interventions for Anxiety

10 - 20
All Sexes
Sugar Land, TX

The goal of this clinical trial is to learn if psychology and music based interventions can impact anxiety and overall wellbeing in adolescents enrolled in choral music classes. The main questions it aims to answer are: Do specific psychology and music based breathing interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based performance anxiety reduction interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based emotion regulation interventions impact anxiety and overall wellbeing in adolescents? Researchers will compare results of pre-test data, post-test data, qualitative interviews, and surveys of adult choral directors to see if there is a measurable impact on adolescent anxiety and overall wellbeing. Participants will: * Use box breathing during choral music warm-ups to connect choral breathing to breathing for anxiety reduction * Use "magnify" technique to compare cognitive distortions regarding an upcoming performance that may cause anxiety to the most likely realistic outcome * Use emotion regulation through song lyrics technique to connect lyrics of choral music repertoire to participants experienced emotions

Waitlist Available
Has No Placebo

Fort Bend ISD

Jane Kuehne, PhD

Have you considered Silenor clinical trials?

We made a collection of clinical trials featuring Silenor, we think they might fit your search criteria.
Go to Trials